We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Noninvasive Test for Fetal RHD Genotype (NAFTnet RHD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00871195
First Posted: March 30, 2009
Last Update Posted: May 10, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
NAFTNet
Information provided by (Responsible Party):
Sequenom, Inc.
  Purpose
The objective of this study is to evaluate the performance of Sequenom's noninvasive test for fetal RHD genotype. The test uses MALDI-TOF mass spectrometry to detect DNA. The study is specifically designed to determine whether RHD typing using free fetal DNA in maternal circulation can accurately predict the neonatal RhD phenotype at birth.

Condition
Rhesus D Genotype

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation Of The Performance Of A Noninvasive Test For Fetal RHD Genotype On The Sequenom MassARRAY System

Further study details as provided by Sequenom, Inc.:

Primary Outcome Measures:
  • To test as to whether advancing gestational age is associated with accuracy of fetal typing for RhD. [ Time Frame: First, second, and third trimester ]

Biospecimen Retention:   Samples With DNA
Plasma and buffy coat.

Enrollment: 520
Study Start Date: April 2009
Study Completion Date: April 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Detailed Description:

In the United States and Canada, routine obstetrical care includes a blood test to determine the blood type of the mother (ABO and RhD). An antibody screen for anti-red cell antibodies in the mother's serum is also performed.

Postpartum prophylactic treatment of RhD negative women with anti-D immunoglobulin to prevent "RhD Disease", or hemolytic disease of the fetus/newborn, was initiated in the 1960's. In the mid 1980's, the routine administration of antenatal anti-D immunoglobulin became the standard of care as well. Although these treatments have dramatically reduced the incidence of RhD Disease, approximately 40% of all RhD negative pregnancies continue to receive unnecessary injections of antenatal anti-D immunoglobulin.

Genotyping platforms such as MALDI-TOF mass spectrometry allow for precise and sensitive detection of fetal-specific (paternally derived) alleles in maternal plasma. In this study, Sequenom's MassARRAY technology will be used to assess a noninvasive test for fetal RHD genotyping in a clinical setting.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pregnant women who are known to be serologically RhD negative.
Criteria

Inclusion Criteria:

  • Female at least 18 years of age
  • RhD negative by serology
  • Pregnant at no more than 11-13 weeks gestation confirmed by ultrasound
  • Willing to provide signed and dated informed consent
  • Able and willing to comply with the protocol

Exclusion Criteria:

  • RhD negative women known to be alloimmunized to the RhD antigen
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00871195


Locations
United States, Arizona
Obstetrix Medical Group of Phoenix
Phoenix, Arizona, United States, 85006
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
United States, New York
Columbia University
New York City, New York, United States, 10032
Mt. Sinai School of Medicine
New York, New York, United States, 10029
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Good Samaritan Hospital
Cincinnati, Ohio, United States, 43210
Ohio State University
Columbus, Ohio, United States, 45211
United States, Pennsylvania
Thomas Jefferson
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Washington
Evergreen Hospital
Kirkland, Washington, United States, 98034
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada, V6H 3N1
Canada, Ontario
Mt. Sinai School of Medicine
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
McGill University
Montreal, Quebec, Canada, H3A 1A1
Sponsors and Collaborators
Sequenom, Inc.
NAFTNet
Investigators
Principal Investigator: Kenneth Moise, MD Baylor College of Medicine
  More Information

Responsible Party: Sequenom, Inc.
ClinicalTrials.gov Identifier: NCT00871195     History of Changes
Other Study ID Numbers: SQNM-RHD-301
First Submitted: March 26, 2009
First Posted: March 30, 2009
Last Update Posted: May 10, 2012
Last Verified: May 2012

Keywords provided by Sequenom, Inc.:
Rhesus D
RHD
genotype
phenotype
neonatal
noninvasive
fetal
MassARRAY
DNA


To Top